Navigation Links
Lilly Reports First-Quarter 2013 Results
Date:4/24/2013

INDIANAPOLIS, April 24, 2013 /PRNewswire/ --

  • Worldwide revenue was flat as growth in key products offset lower Zyprexa revenue following patent expirations.
  • Cymbalta revenue increased 19 percent while Cialis increased 11 percent.
  • Expense controls resulted in lower SG&A, offsetting growth in R&D expense.
  • First quarter 2013 results include income of $495 million related to the transfer to Amylin of exenatide commercial rights outside of the U.S.
  • Tax rate comparisons benefited from the reinstatement of the U.S. R&D tax credit.
  • First quarter earnings per share grew to $1.42 (reported), or $1.14 (non-GAAP).
  • 2013 earnings per share reconfirmed to be in the range of $4.10 to $4.25 (reported), or $3.82 to $3.97 (non-GAAP).
  • Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2013.$ in millions, except per share data

    First Quarter

    %20132012

    GrowthTotal Revenue – Reported

    $5,602.0$5,602.0

    0%Net Income – Reported

    1,548.01,011.1

    53%EPS – Reported

     

    1.420.91

    56%Net Income – non-GAAP

    1,247.71,026.9

    22%EPS – non-GAAP

    1.140.92

    24% 

    Financial results for 2013 and 2012 are presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the period. Non-GAAP results exclude the items described in the reconciliation tables later in the release. The non-GAAP results are presented in order to provide additional insights into the underlying trends in th
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. DiversityInc Names Lilly a Top Company for Diversity
    2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
    4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
    5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
    6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
    7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
    8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
    9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
    10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
    11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)...   Fruit Street Health (Fruit Street), today ... of funding. The round, which includes ... of individual investors, the majority of whom are prominent ... round are; Houston Cardiology Consultants Partner Asif Ali, ... Rapha Family Medicine Practice Owner Frances Ilozue , ...
    (Date:9/18/2014)...  KIYATEC announced today that it has been ... (SBIR) Phase II Contract from the National Cancer ... centers that comprise the National Institutes of Health ... award, KIYATEC will expand its 3D breast cancer ... of cancer therapy strategies: 1) cancer,s interaction with ...
    (Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
    Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
    (Date:9/18/2014)... led by Queen,s University professor Robert Campbell (Ophthalmology) has ... not helpful or necessary., Glaucoma is the most common ... 400,000 Canadians are afflicted with the disease, which is ... enough to damage the optic nerve. The optic nerve ... the brain and is a vital part of vision., ...
    (Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
    (Date:9/18/2014)... It is almost time to park your ... healthier and happier kids. The South Florida Hyundai Dealers ... Annual Miami Children’s Hospital 5K Run/Walk. Its title sponsor ... , The 5K will take place on Saturday August 20th. ... Coral Gables City Hall located at 405 Biltmore Way. ...
    (Date:9/18/2014)... Research conducted by a team of ... has documented improved survival in patients with cancerous ... tumors along with stereotactic radiosurgery. , The study was ... (American Society for Radiation Oncology) this week in San ... radiation beams to treat tumors in the brain, delivering ...
    (Date:9/18/2014)... and London. (PRWEB) September 18, 2014 ... Computer Aided Engineering software, today announced its new partnership ... be utilizing the CD-adapco simulation tool, STAR-CCM+® in the ... just announced its participation in the 35th America’s Cup ... 35th edition of the America’s Cup is sustainability, the ...
    Breaking Medicine News(10 mins):Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2
    ... studying rare genetic disorders have uncovered insights into ... when cells divide. Focusing on the cohesin complex, ... encircles chromosome pairs, scientists have discovered mutations that ... diseases called cohesinopathies. "We are learning more ...
    ... Israel; Seoul, South Korea, May 29, 2012 -- The ... enabled an Israeli-South Korean scientific team to conduct a genetic ... B virus (HBV) genotype C2 sequence common in Southeast Asia. ... be used as a model to study the evolution of ...
    ... Texas For 50 years scientists have been unsure how the ... basic innate immune responses. That mystery has now been solved, thanks ... The answers may help clear the way for a ... such as V. cholerae , but instead disable their defenses ...
    ... battle: Long after a cancer has been beaten into remission, it ... is unclear. New research led by Weizmann Institute scientists shows that, ... cancer recurrence is in a set of cells that do not ... survive chemotherapy. The findings, which appeared today in the journal ...
    ... not healthy. However, new research from the University of Copenhagen ... vitamin is not good either. The study is based on ... published in the reputed scientific Journal of Clinical Endocrinology ... calcium reach our bones, thus lessening the risk from falls ...
    ... , MONDAY, May 28 (HealthDay News) -- Women who work ... increasing their risk for breast cancer, Danish researchers find. ... women who describe themselves as "morning" people rather than "evening" ... of women in modern societies have night shift work," said ...
    Cached Medicine News:Health News:Mutations impair childhood growth and development by disrupting organization of chromosome pairs 2Health News:16th-century Korean mummy provides clue to hepatitis B virus genetic code 2Health News:50-year cholera mystery solved 2Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:Too much vitamin D can be as unhealthy as too little 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 3Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 4
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: